Blog
ADA Assays Screening Viral Vectors For Gene Therapy
By integrating modified or new genes into the cells of the human body, gene therapy has the potential to treat a wide variety of acquired and inherited diseases. Genetic therapeutics must deliver the intended genetic material to a large quantity of specific cells within the correct tissue. Properly targeting cells requires that the genetic material…
Immuno-Oncology BioA: Pre-Existing ADAs Affecting PK
When administering human monoclonal antibodies, reconstituted human proteins, and antibody drug conjugates (ADCs), anti-drug antibodies (ADAs) can form and affect the Biotherapeutic’s exposure, bioavailability, and pharmacodynamic effects. The qualities of these ADAs – such as their specificity, magnitude, timing, maturity, and affinity – can impact pharmacokinetics (PK) and pharmacodynamics (PD). Challenges Presented by ADAs in…
Sword Bio Appoints Kara Harrison as Vice President, Quality Assurance
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for research, pre-clinical and clinical trials, announces the appointment of Kara Harrison as VP of Quality Assurance. Kara joins Sword with a proven record of leading and scaling quality management programs and initiatives. Most recently, she was VP,…
Streamline Immunogenicity Assay Development: Expedite Research Workflows by Understanding the Issues with ADA Assays
The biotech industry is rapidly modifying and developing biotherapeutics into complex large molecules with specificity moieties and multiple functional domains to produce a specific biological method of action. (ADC, ACC, Bi-specific antibodies, Fusion proteins, recombinant-modified proteins, etc.) Therefore, developing LBA assays to detect the immunogenicity of these biotherapeutics is becoming very complex due to this…
Sword Bio Appoints John Pirro as Director of Scientific Solutions
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of John Pirro as Director of Scientific Solutions. John joins Sword with a proven track record in the contract research space, providing scientific insight, guidance, and consultation. Most recently, he…
Sword Bio Appoints David Osband as EVP, Sales & Marketing
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of David Osband as EVP, Sales & Marketing. David joins Sword with a proven track record in the contract research space. Most notably, he was an owner of Cambridge Biomedical,…
Sword Bio Appoints Matthew Langevin as Chief Operating Officer
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs from development to clinical trials, announces the appointment of Matthew Langevin as Chief Operating Officer. Matt joins Sword with exceptional experience and a proven track record in the contract research space. Most notably, he was Co-Founder of BioAgilytix,…